Transforming Patient Care: The Role of AI and Data Literacy in a New Era
A new publication by FINN Partners highlights the shift from static health records to intelligent, adaptive tools, focusing on personalized care
Read More
Rise of New COVID Variants Sparks Concern Across U.S. Regions
Cases are escalating in nine U.S. states
Stress Test: OBBBA, Rural Fragility, and Innovation
Clinging to our old models is equivalent to waiting for failure. We need to embrace the tools, team structures, and delivery models that this ongoing crisis demands. The post Stress Test: OBBBA, Rural Fragility, and Innovation appeared first on MedCity News.
Unlocking AI Explainability for Trustworthy Healthcare
AI should augment, not replace, human provider expertise. Explainability empowers healthcare professionals to work in tandem with AI, ensuring that patients receive the most accurate and informed care. The post Unlocking AI Explainability for Trustworthy Healthcare appeared first on MedCity News.
He Went in for a Colonoscopy. The Hospital Charged $19,000 for Two.
Tom Contos is an avid runner. When he started experiencing rectal bleeding in March, he thought exercise could be the cause and tried to ignore it. But he became increasingly worried when the bleeding continued for weeks. The Chicago health care consultant contacted his physician at Northwestern Medicine, who referred him for a diagnostic colonoscopy,…
Health Care Heartaches: Your Winning Health Policy Valentines
Health policy has never looked so flirtatious. Every year, our readers send us valentines that make us swoon, laugh, and occasionally clutch our insurance cards. And in 2026, you did not hold back. You wrote about overcharging, rising insurance, AI in health care, and more. Here are some of our favorites, starting with the poem that stole…
Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to 18% Weight Loss in Key Study
The Phase 3 results in China are encouraging for Kailera Therapeutics, which holds rights to the molecule in the rest of the world. The startup is preparing a global clinical development program for this drug, a once-weekly injectable GLP-1 and GIP receptor agonist. The post Hengrui Pharma’s Potential Rival to El Lilly’s Zepbound Leads to…
Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare Disease With No Approved Drugs
Glycomine’s lead program is an experimental treatment for PMM2-CDG, an ultra-rare enzyme deficiency often misdiagnosed as cerebral palsy. With encouraging results from an open-label Phase 2 study, the biotech startup is now preparing for a placebo-controlled test that could potentially support a regulatory submission. The post Startup Glycomine Lands $115M for Clinical Trial in Ultra-Rare…
Utilization of Health Care Services by Medicaid Expansion Status
Some critics of Medicaid expansion have argued that expansion diverts resources away from other groups of Medicaid enrollees, including people with disabilities and children, and that expansion enrollees are “able-bodied” implying they have minimal health care needs. However, data show that expansion states spend more per enrollee overall and on each eligibility group than non-expansion…
A Look at New or Expanded Medicaid and Public Health Partnerships from 2025: Findings from A Survey of State Medicaid Programs
State Medicaid and public health agencies both work to advance the health of their communities, often pursuing similar priorities and serving similar populations. This brief examines findings from KFF’s 25th annual Medicaid budget survey, which asked state Medicaid directors about new or enhanced initiatives involving public health in FY 2025 or planned for FY 2026.